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Abstract
Background:  Prostaglandin E2 (PGE2) has multiple physiologic roles mediated by G protein
coupled receptors designated E-prostanoid, or "EP" receptors. Evidence supports an important
role for the EP2 receptor in regulating fertility, vascular tone and renal function.
Results: The full-length rabbit EP2 receptor cDNA was cloned. The encoded polypeptide contains
361 amino acid residues with seven hydrophobic domains. COS-1 cells expressing the cloned rabbit
EP2 exhibited specific [3H]PGE2 binding with a Kd of 19.1± 1.7 nM. [3H]PGE2 was displaced by
unlabeled ligands in the following order: PGE2>>PGD2=PGF2α =iloprost. Binding of [3H]PGE2 was
also displaced by EP receptor subtype selective agonists with a rank order of affinity consistent with
the EP2 receptor (butaprost>AH13205>misoprostol>sulprostone). Butaprost free acid produced
a concentration-dependent increase in cAMP accumulation in rabbit EP2 transfected COS-1 cells
with a half-maximal effective concentration of 480 nM. RNase protection assay revealed high
expression in the ileum, spleen, and liver with lower expression in the kidney, lung, heart, uterus,
adrenal gland and skeletal muscle. In situ hybridization localized EP2 mRNA to the uterine
endometrium, but showed no distinct localization in the kidney. EP2 mRNA expression along the
nephron was determined by RT-PCR and its expression was present in glomeruli, MCD, tDL and
CCD. In cultured cells EP2 receptor was not detected in collecting ducts but was detected in renal
interstitial cells and vascular smooth muscle cells. EP2 mRNA was also detected in arteries, veins,
and preglomerular vessels of the kidney.
Conclusion: EP2 expression pattern is consistent with the known functional roles for cAMP
coupled PGE2 effects in reproductive and vascular tissues and renal interstitial cells. It remains
uncertain whether it is also expressed in renal tubules.
Background
Prostaglandin E2 is a major cyclooxygenase metabolite of
arachidonic acid which exerts diverse effects on vascular
smooth muscle tone and epithelial solute transport via G-
protein coupled receptors [1,2]. At least four distinct G-
protein coupled PGE2 receptors have been cloned: the
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EP1, EP2, EP3, and EP4[1]. Pharmacological studies sug-
gest PGE2 relaxes vascular smooth muscle through two of
these receptors, the EP2 and EP4 receptors, which couple
to cyclic-AMP generation [3]. In contrast, PGE2 constricts
other vascular smooth muscle through EP3 receptors
which inhibit cAMP generation via Gi or EP1 receptors
which increase Ca2+ mobilization [3]. Although both EP2
and EP4 receptors relax smooth muscle, EP2 receptors are
uniquely sensitive to the agonists butaprost and AH13205
[3,4]. Previous studies have shown that PGE2 increases the
cAMP concentration in many tissues including kidney, in-
testine and uterus, but the relative contribution of EP2 ver-
sus EP4 receptors to these effects is incompletely defined
[5,6]. Recent studies in mice with targeted disruption of
these receptors have suggested an important role for EP2
receptor in regulating systemic hemodynamics. Deficien-
cy of the EP2 receptor is associated with a defect in coun-
teracting vasopressor effect of PGE2 [7] and the
development of salt sensitive hypertension [8], suggesting
a predominant normal vasodepressor role of EP2 receptor
in blood pressure regulation.
The vasodepressor action of PGE2 may also play an im-
portant role in the kidney. It has been previously shown
that PGE2 not only directly dilates renal arteries [9–11]
but also attenuates the AngII-induced increase in renal
vascular resistance [12] through inhibition of AngII-elicit-
ed intracellular Ca++ increase in vascular smooth muscle
cells of preglomerular vasculature [13]. Based on the fact
that PGE2 stimulates cAMP generation in freshly isolated
preglomerular renal arterioles [14], the cAMP-stimulating
EP2 or EP4 receptor has been thought to mediate these ef-
fects of PGE2 on renal resistance vessels.
There is also evidence suggesting that intrarenal EP2 and
EP4 receptor activates cAMP-stimulated salt and water
transport along the nephron [15–18]. Although the local-
ization of EP1, EP3 and EP4 has been determined in hu-
man kidney by in situ hybridization, segmental
distribution of cAMP-coupled EP2 receptor along the ne-
phron was not detected by this method [19]. To more
clearly define the physiologic role of this cAMP coupled
EP receptor, we cloned the rabbit EP2 receptor, character-
ized its pharmacology and signaling. These studies also
defined the tissue distribution with a focus on vascular,
intrarenal and reproductive localization of the rabbit EP2
receptor mRNA.
Results
Receptor isolation
Screening of 5 ×  105 plaques from a rabbit genomic li-
brary using a full-length human cDNA for the EP2 recep-
tor resulted in isolation of two independent clones
designated 4B1 (13 kb) and 6A (11 kb). A 5' coding exon
of EP2 receptor was contained in clone 4B1, while a 3'
coding exon was contained in clone 6A. Sequence data in-
dicated that the entire coding region was present in these
two exons. A potential translation initiation codon in the
NotI/BamHI fragment (3 kb) of clone 4B1 starts an open
reading frame that encodes a polypeptide sequence highly
homologous to the first six transmembrane domains of
the human EP2 receptor [20]. The amino acid sequence of
the open reading frame in the NotI fragment (6 kb) of
clone 6A was homologous to the seventh transmembrane
domain (TMD VII), followed by a short C-terminal tail
and an in-frame stop codon. An intron with a donor and
acceptor splice site was located following the coding re-
gion corresponding to the sixth transmembrane domain
of the protein.
A functional cDNA clone was obtained by screening a rab-
bit uterus cDNA library using a 700 bp AvaII cDNA frag-
ment from clone 4B1. Two types of positive overlapping
clones (18A and REP2-2.7) were isolated. Of the 18 posi-
tive cDNA clones isolated, 8 belonged to the type desig-
nated REP2-18A, and 10 clones belonged to the type
designated REP2-2.7. Sequence analysis indicated that
these two cDNAs possess an identical open reading frame
and 1,664 bp of down-stream 3' untranslated region
(3'UTR), however clone REP2-18A possesses an 467 addi-
tional base pairs in the 3'UTR compared with REP2-2.7. It
is also noted that there are 6 and 7 AUUUA motifs in 3'
UTR of REP2-2.7 and REP2-18A, respectively, suggesting
an instability of rabbit EP2 receptor mRNA in vivo.
Because both rabbit EP2 cDNA clones, 18A and REP2-2.7,
lacked ~50 codons corresponding to the 5' end of the hu-
man EP2 receptor and which were present in the rabbit ge-
nomic sequence, a full-length sequence of the rabbit EP2
was constructed by ligating a SacII/XhoI cDNA fragment
(nucleotide 340–1655) from the cDNA clone 18A with
the upstream Hind III/SacII fragment (nucleotide 1–340)
of the rabbit genomic clone. This created an open reading
frame of 1,083 base pairs with an in-frame TGA stop co-
don. The existence of this 5' UTR sequence in native cDNA
was confirmed by RT-PCR on RNA isolated from rabbit
uterus (data not shown). The predicted polypeptide is
comprised of 361 amino acids with a calculated molecu-
lar weight of ~40 kDa. Its hydrophobic profile reveals the
presence of seven hydrophobic stretches characteristic of
G-protein-coupled receptors [20] (Fig. 1). Comparison of
the deduced amino acid sequence of rabbit EP2 with hu-
man and mouse EP2 shows 90% and 82% sequence iden-
tity, respectively (Fig. 1).
Ligand binding properties of the EP2 receptor
The putative rabbit EP2 receptor was pharmacologically
characterized using membranes from COS-1 cells tran-
siently transfected with a rabbit EP2 expression vector,
pcDNA3/REP2. Membranes from EP2 receptor transfectedBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/14
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COS-1 cells, exhibited saturable [3H]PGE2 binding with a
dissociation constant of 19.1 ± 1.7 nM, and a maximum
binding capacity (Bmax) of 2.8 pmol/mg of membrane
protein. Radioligand binding studies were performed us-
ing various prostanoids and EP-receptor subtype-specific
agonists to compete for PGE2 binding. Competition bind-
ing experiments revealed a rank order affinity consistent
with an EP receptor: PGE2 >> iloprost = PGD2 = PGF2α
(Fig. 2A). [3H]PGE2 binding was partially displaced by the
EP2/3/4 agonist misoprostol and was not displaced by the
EP1/3 agonist sulprostone (Fig. 2B). Furthermore, the EP2
selective agonists butaprost free acid and AH13205 com-
peted for [3H]PGE2 binding with Ki values of 3–7 µM and
3–4 µM, respectively, suggesting this receptor is the rabbit
EP2 receptor [20,21].
Signal transduction properties of the EP2 receptor
Incubation of EP2-transfected COS1 cells with butaprost
free acid produced a concentration-dependent increase in
cAMP accumulation with an EC50 of 480 nM (Fig. 3).
Cells transfected with the vector alone demonstrated no
significant increase in cAMP in response to butaprost free
acid.
Tissue distribution of the rabbit EP2 receptor
Solution hybridization/RNase protection assays with a ra-
diolabeled antisense EP2 riboprobe resulted in a RNase-
resistant fragment of the appropriate size (322 bp, Fig. 4).
EP2 receptor mRNA was detected in several tissues includ-
ing ileum, spleen, and liver. Lower expression was found
in kidney, uterus, lung, heart, liver, adrenal gland, brain,
urinary bladder and skeletal muscle. Furthermore, EP2 re-
ceptor mRNA was detected by RNase protection assay in
all blood vessels examined (Fig. 5) including arteries and
veins of large and small caliber (Fig. 5A & 5C), and renal
preglomerular vasculature (Fig. 5B). The expression level
of the EP2 receptor mRNA in these vessels was comparable
to that of the EP4 receptor (Fig. 5). EP2 receptor mRNA
was also detected in vascular smooth muscle cells cultured
from rabbit aorta (Fig. 6A).
Figure 1
Alignment of the deduced amino acid sequence of rabbit EP2
(rabEP2) with human (hEP2) and mouse EP2 (mEP2). Under-
lined sequences denote transmembrane domains. Sequences
were deduced from cDNA sequences and aligned using
CLUSTALV program. (*) = identical sequence; (·) = con-
served sequence. (-)= gaps in sequence alignment. (GenBank
accession number (pending).
ra bEP2 M GNASN DSR-P EDCETRQWL PSGESPAISAVMFSA GVLGN LIALALLARRW RADA GRSAG
hEP2  MGNASN DSQ-S EDCETRQWL PPGESPAISS VMFSA GVLGN LIALALLARRW RGDV GCSAG
mEP2  MDNFLNDSKLM EDCK SRQWL LSGESPAISS VMFSA GVLGN LIALALLARRW RGDT GCSAG
 * . *  * **. *** . **** .*** ****. ***** ***** ***** ***** **.* *  ***
ra bEP2 RGTSLSLFHVLVTELVFTDLLGTCFI SPVVLASYA RNQTLVALEPDGRAC TYFAFAMTFF
hEP2  R RSSLS LFHVLVTELVFTDLLGTCLI SPVVLASYA RNQTLVALAPESRACTYFAFAMTFF
mEP2  S RTSIS LFHVLVTELVLTDLLGTCLI SPVVLASYSRNQTLVALAPESHACTYFAFTMTFF
.*.* ***** **** *.*** ****. ***** ****. ***** *** *. ..** ***** . ****
ra bEP2 SLATML M LFAM ALERYLSIG HPYFYQCRIT RRGGL AVLPAI YTASLLFCSLPLLDYGEYV
hEP2  S LATML M LFAM ALERYLSIG HPYFYQRRVSASGGLAVLPVI YAVS LLFCSLPLLDYGQYV
mEP2  S LATML M LFAM ALERYLSIG YPYFYRRHLSRRGGL AVLPVI YGAS LLFCSLPLLNYGEYV
 * ***** ***** **** ***** **** .  ...  *** **** **  * ***** ****. **.**
ra bEP2 QYCPGTW CFIR HGRTAYLQLYATLLLLLIV AVLAC NLSVI CNLVH M YRRA RRSRCGPSSG
hEP2  Q YCPGTW CFIR HGRTAYLQLYATLLLLLIV SVLAC NFSVI LNLIRM HRRSRRSRCGPSLG
mEP2  Q YCPGTW CFIR HGRTAYLQLYATML LLLIV AVLAC NISVI LNLIRM HRRSRRSRCGLSGS
 * ***** ***** **** ***** ***.* ***** . **** *.*** **.. * **. ***** * * .
ra bEP2 SGRGGPGTRRRGERVSVAEETDHLILLAIMTITFA VCSLPFTIFA YMNET SSRKEKWDLQ
hEP2  S GRGGPGARRR GERVSMAEE TDHLILLAIMTITFA VCSLPFTIFA YMNET SSRKEKWDLQ
mEP2  S LRG-P GSRRRGERTSMAEE TDHLILLAIMTITFA I CSLPFTIFA YMDET SSLKEKWDLR
 * ** **.*** *** *.*** ***** ***** ***** . **** ***** **.** ** ** ****.
ra bEP2 ALRFLSI NSII DPWV FAILRPSVLRLMRSV LCCRV SLRTQDATQTSCSTQSNASK QADLC
hEP2  A LRFLSI NSII DPWV FAILRPPVLRLMRSV LCCRISLRTQDATQTSCSTQSDASK QAD--
mEP2  A LRFLSVNSII DPWV FAILRPPVLRLMRSV LCCRTSLRTQEAQQT SCSTQSSASKQTDLC
 * ***** . **** **** ***** *.*** ***** **** ***** . * ** ***** * *** *.*
ra bEP2 GQX
hEP2  - - L
mEP2  G QL
TM1
TM2 TM3
TM4
TM5
TM6
TM7
Figure 2
Competition binding profile of the EP2 receptor expressed in
COS-1 cells. Membranes were incubated with 1.5–2 nM
[3H]PGE2 and varying concentrations of competitors. The
data shown are from a single experiment performed in tripli-
cate and are representative of three to four experiments.
Panel A:  PGE2; Ћ PGF2a; Њ PGD2; ♦  iloprost. Panel B: 
butaprost free acid; ?? AH13205; Ќ misoprostol; ◊ sulpros-
tone.
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Intrarenal localization of the rabbit EP2 receptor
In situ hybridization was performed to examine the distri-
bution of the EP2 receptor gene expression in the kidney
and uterus. Sections of rabbit renal and uterine tissues
were hybridized with the [35S]-labeled riboprobe from
the same cDNA probe used in RNase-protection assays. As
observed for the mouse EP2 in the uterus, a significant hy-
bridization signal was detected mainly in the endometrial
epithelium of the rabbit uterus with less expression in my-
ometrium (Fig. 7). Consistent with previous observation
in man [19], only a diffuse weak EP2 mRNA signal was de-
tected in the rabbit kidney (Figure 7). To further elucidate
the distribution of EP2 receptor along the nephron, neph-
ron segments were dissected and expression of EP2 was
determined using RT-PCR. As shown in figure 8, PCR
products with expected sizes were obtained for both EP2
receptor (336 bp) and GAPDH (411 bp). Identity of the
amplified products was confirmed by Southern hybridiza-
tion (not shown) and sequencing. As positive control, RT-
PCR was performed using 1 µg of total RNA isolated from
rabbit spleen (figure 8). As negative control, PCR were
also performed in the absence of reverse transcription
without identifiable product, indicating the origination of
PCR products were from mRNA other than genomic DNA
(figure 8). EP2 receptor mRNA was easily detected in
glomeruli and medullary collecting ducts (MCD). Detect-
able EP2 mRNA was also present in thin descending limbs
of Henle (tDL) and cortical collecting ducts (CCD).
In cultured cells RNase protection assay detected EP2 ex-
pression in renal medullary interstitial cells (MICs), while
no signal was detected in cultured cortical collecting ducts
or glomerular mesangial cells (Fig. 6B & 6C). EP2 mRNA
was also detected in cultured rabbit aortic vascular
smooth muscle cells (Figure 6A).
Discussion
The present studies describe the cloning and characteriza-
tion of the rabbit EP2 receptor. With this information,
cDNA sequence for all four rabbit EP receptors is now
available [22–24]. Several similarities between the rabbit
and mouse EP2 receptors exist [5,21]. The rabbit EP2 ge-
nomic clone contains an intron with consensus splice do-
nor and acceptor sites near the end of transmembrane
domain (TM) VI. The relative position of the intron to the
coding regions is also identical to that found in the hu-
man TP, the human and mouse DP, and the human EP1
gene [2]. This provides further evidence that the prosta-
noid receptor family arose from a common ancestral gene.
The rabbit EP2 gene contains a 1,083 bp open reading
frame coding for a 361 amino acid polypeptide, with a
calculated molecular weight of 39,919 Daltons. Its amino
acid profile reveals the presence of seven hydrophobic re-
gions which likely represent transmembrane domains.
Unlike the TP and EP3 receptors, no alternative splicing in
the EP2 receptor was found in the coding region [21,25].
Diversity of EP2 mRNAs in the mouse was found in both
the 5' UTR and the 3' UTR [21]. Similar diversity in the 3'
sequence of the rabbit EP2 receptor cDNA clones isolated
from the uterine library was observed in the present stud-
ies. The significance of this mRNA splicing is not yet
known, but it might play a role in stability or translation
efficiency of EP2 transcripts [21].
Figure 3
Butaprost free acid mediated stimulation of intracellular
cAMP production in COS-1 cells transfected with the rabbit
EP2 receptor. Cells were incubated with various concentra-
tions of PGE2 in the presence of IBMX for 5 minutes. The
reactions were stopped with 10% TCA, and cell lysates were
analyzed for cAMP content by a cAMP EIA kit. The data
shown are from a single experiment and are representative
of 3 independent experiments. Њ rabbit EP2 transfected; 
vector only transfected.
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Figure 4
RNase protection assay demonstrating the distribution of
EP2 and GAPDH mRNA in normal rabbit tissues. The pro-
tected fragments were electrophoretically separated on a 6%
agarose/7 M urea gel. The film was exposed for 36 hours. A
100 bp ladder was used as a size marker. Densitometry was
used to quantitate EP2 mRNA expression, RNA loading was
corrected by normalizing to GAPDH mRNA expression.
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Ligand binding studies confirm that the rabbit EP2 recep-
tor preferentially binds PGE2 with significantly higher af-
finity than other endogenous prostanoids. Its low affinity
for PGD2, PGF2α , iloprost, misoprostol and sulprostone
suggest it is not an EP1, EP3 or IP receptor [2,3]. As dem-
onstrated for the EP2 receptor in other species [6,20,21],
butaprost free acid and AH 13205, two synthetic PG ago-
nists with selectivity for the EP2 subtype, efficiently and
dose dependently compete for [3H] PGE2 binding to this
newly cloned rabbit receptor. Inhibition of PGE2 binding
to the rabbit EP2 receptor by AH13205 is about 100 times
greater than that to rabbit EP4 in transfected COS-1 cells
(unpublished data). Finally, the EP2 selective agonist but-
aprost free acid dose-dependently stimulated cAMP gener-
ation in COS-1 cells transfected with the rabbit EP2
receptor. These results are in agreement with observations
with human, rat and mouse EP2 receptors [6,20,21],
which also couple to cAMP generation. Taken together,
these results clearly demonstrate that the pharmacology of
this receptor corresponds to an EP2 receptor rather than
an EP4 receptor.
The expression level of rabbit EP2 receptor mRNA is rela-
tively low. Nuclease protection analysis demonstrated
rabbit EP2 expression is highest in ileum, liver, and
spleen, with a lower expression in kidney, uterus, brain,
adrenal gland, lung, heart, bladder, stomach and skeletal
muscle. This mRNA expression pattern is similar to that of
the EP2 in the mouse [5,21]. PGE2 has been reported to
stimulate cAMP formation in many tissues, including in-
Figure 5
RNase protection assay demonstrating the distribution of EP1, EP2, EP3, EP4 and GAPDH mRNA in rabbit vascular tissues. The
protected fragments were electrophoretically separated on a 6% agarose/7 M urea gel. The film was exposed for 36 hours. A
100 bp ladder was used as a size marker. Panel A: EP1, EP2, EP3, and EP4 expression in rabbit aorta. Panel B: EP2 and EP4
expression in preglomerular microvessels in the kidney. Panel C: EP2 expression in the rabbit ear artery, jugular vein and vena
cava.
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testine, microdissected renal tubule segments, and uterus
via butaprost sensitive and insensitive receptors [14,26–
29]. The mRNA expression results are consistent with
these functional studies and suggest that the EP2 receptor
plays important roles in mediating PGE2 stimulated
cAMP generation in these tissues [14,21,26–33].
The presence of the rabbit EP2 receptor mRNA in the uter-
us also support a role for this receptor as an important me-
diator of PGE2 action in this organ. This is in agreement
with previous studies which demonstrate that EP2 is ex-
pressed and highly regulated in uterine luminal epitheli-
um cells by ovarian steroids during the peri-implantation
Figure 6
RNase protection assay demonstrating EP2 and EP4 expression in cultured vascular smooth muscle cells isolated from the rab-
bit aorta (Panel A), cultured cortical collecting duct cells (CCD) (Panel B) and cultured glomerular mesangial cells (MCs) and
medullary interstitial cells (MICs) (Panel C). To determine the regulation of EP2 expression in MCs and MICs, cells were
treated with 1 µM phorbol 12-myristate 13-acetate (PMA) for 6 hours and EP2 mRNA level was examined by Nuclease protec-
tion assay (Panel C).
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period [5,21,34,35]. The change in level of the EP2 recep-
tor expression in the uterus may contribute to the increase
in GS protein content and cAMP concentration in mid-
gestation and the decrease at term [26,27]. Because the
EP2 receptor is a GS-coupled cAMP-stimulating receptor,
the EP2 receptor may participate in the physiological reg-
ulation of uterine relaxation during pregnancy and the
transition into uterine contraction at the onset of the la-
bor. Lack of normal uterine EP2 expression may also con-
Figure 7
In situ hybridization of rabbit EP2 showing mRNAdistribution in rabbit kidney (A) and uterus (B). A: autoradiographydemon-
strating low and ubiquitous expression of EP2 mRNA expression inrabbit kidney. Dark black areas indicate regions of hybridi-
zation with the antisense riboprobe (right panel). In contrast, no hybridization was seen using a sense probe (left panel). B: In
situ hybridization showing rabbit EP2 mRNA signals in the uterus. Autoradiography (left panels) and photomicrograph (right
panel, 400 Xdarkfield, white grains) showing specific hybridization of the antisense probe to uterus endometrium.
A.
B.
Sense Antisense
Sense
AntisenseBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/14
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tribute to implantation defect reported in EP2
-/- mice
[8,36].
PGE2 also plays a critical role in regulating systemic blood
pressure [37,38]. Although the receptor mediating the
predominant vasodilator effect of PGE2 remains only par-
tially defined, recent gene targeting studies suggest that
the EP2 receptor may be an important vasodilator in vi-
vo[7,8]. The rabbit ear artery has been used as a classic
pharmacological model of an EP2 responsive tissue, while
the rabbit jugular vein has been proposed to be an EP4
bearing target tissue [3,4,39], however in the present stud-
ies EP2 receptor mRNA was detected in both vessels. EP2
mRNA expression was also detected in the rabbit aorta
and inferior vena cava thus providing further evidence
that the EP2 receptor is functionally expressed in both ar-
teries and veins. Expression of this GS-coupled cAMP-
stimulating PGE2 receptor in cultured vascular smooth
muscle cells isolated from the aorta supports a direct role
of the EP2 receptor in mediating vascular relaxation.
PGE2 has also been shown to stimulate cAMP formation
in several renal tissues, notably preglomerular microvas-
culature [14], renal glomeruli [40], thin descending limb
[41], medullary and cortical thick ascending limb, and
collecting duct [29,42]. Although EP2 receptor mRNA ex-
pression was detected in the kidney and this was more
pronounced in the renal cortex than in the medulla, no
specific regions of EP2 receptor mRNA expression could
be detected in rabbit kidney by in situ hybridization [19].
Nonetheless, low levels of EP2 receptor mRNA expression
were detected by RT-PCR or RNase protection assay in ne-
phron segments within the kidney including preglomeru-
lar vasculature, glomeruli, thin limbs of Henle's loop and
collecting ducts. The expression of EP2 receptor mRNA in
medullary collecting duct is distinct from functional stud-
ies in the cortical collecting duct where butaprost had no
functional effect [17,18]. These data suggest a possible
unique role for the EP2 receptor in the medullary collect-
ing duct as opposed to cortical collecting duct. Alterna-
tively the PCR detection of EP2 receptor expression in
these microdissected segments might result from the ad-
herent renal interstitial cells other than collecting duct it-
self, since nuclease protection analysis revealed a
relatively high EP2 level in cultured intersitial cells but
failed to detect EP2 expression in cultured collecting duct
cells. It is notable that glomeruli and collecting ducts are
distinguished from other segments by high number of ad-
herent cells. Selective expression of the EP2 receptor in in-
terstitial cells is consistent with a lack of segmental
localization by in situ hybridization. Whether the EP2 re-
ceptor participates in PGE2 stimulated cAMP generation
in epithelial cells along the nephron awaits further inves-
tigation [14,42].
Conclusions
In summary, we have cloned and expressed a butaprost
sensitive rabbit PGE2 receptor that stimulates cAMP for-
mation and is present in many rabbit tissues. Physiologi-
cal effects of PGE2 through the EP2 receptor may mediate
important physiological actions in these tissues. EP2 ex-
pression in uterus, vasculature and the kidney suggests
that this receptor may play important roles in the func-
tions of reproductive system, vascular tissues and intersti-
tium of the kidney.
Materials and Methods
Ligands
Unlabeled PGE2, PGD2, and PGF2α  were purchased from
Cayman Chemical (Ann Arbor). Butaprost free acid was a
gift from Dr. Jilly Evans, Merck-Frosst. Sulprostone, miso-
prostol, iloprost and AH13205 were kindly provided by
Dr. Harold Kluender of Miles Laboratories, P.J. Gardiner
of Bayer UK, Dr. Paul Collins of G.D. Searle, Dr. Rubanie
of Berlex Laboratories and Dr. R.A. Coleman of Glaxo,
UK, respectively. [3H] PGE2 was purchased from Dupont
NEN.
Rabbit genomic library screening
A rabbit genomic library in Lamda DASH® II vector (Strat-
agene) was screened with [32P]-labeled full-length human
EP2 (gift from Dr. D. Woodward, Allergan Pharmaceuti-
cals) [20]. The filters were fixed by ultraviolet light expo-
Figure 8
RT-PCR analysis demonstrating distribution of EP2 receptor
(right upper panel) and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (right lower panel) mRNA along rabbit
nephron. PCR products were electrophoretically separated
on a 1% agarose gel. RNA loading was corrected by normal-
izing to GAPDH mRNA expression. Data are from a single
experiment and represent three independent experiments.
Left panels showing positive and negative control for EP2
(upper) and GAPDH (lower). Note: PCT, proximal convo-
luted tubules; PST, proximal straight tubules; tDL, the thin
descending limb of Henle; TAL, thick ascending limb; DCT,
distal convoluted tubules; CCD and MCD, cortical and med-
ullary collecting ducts.
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sure (Stratalinker, Stratagene) and hybridized 18 hours at
56°C in a solution containing 6X SSC, 5X Denhardt's,
0.1% SDS, 150 µg/ml denatured herring sperm DNA and
3 ×  106 cpm/ml labeled probe. Two representative posi-
tive clones, 4B and 6A, were isolated from 5 ×  105 recom-
binant plaques and shown to exhibit unique restriction
patterns. A XbaI/NotI fragment from clone 4B1 and a NotI
fragment from 6A1 hybridized to the probe and were sub-
cloned in pBluesript II SK(-) (Stratagene) for further anal-
ysis.
cDNA cloning
A rabbit uterus cDNA library in ZAP II (Stratagene) (a gift
from Dr. J. Lytton, Harvard Medical School) was screened
using an AvaII cDNA fragment of 750 bp from the genom-
ic clone 4B1. 106 plaques were probed under high strin-
gency, and 18 positive plaques were purified. The isolated
cDNA-bearing phages were rescued to plasmids according
to the manufacturer's instruction. Clones were analyzed
by restriction digestion, and nucleotide sequencing was
carried out on both strands by the dideoxy chain termina-
tion method.
Construction of an open reading frame of EP2 and its ex-
pression in COS-1 cells
One 5' truncated cDNA clone, REP2-18A, was highly ho-
mologous to the human EP2 receptor but lacked the 5'
150 bp encoding the first 50 amino acids (see results).
REP2-18A was digested by Sac II/Xho I, and the 3' restric-
tion fragment (1,312 bp) was ligated to the Sac II/Hind III
fragment (350 bp) of the 4B1 genomic clone at the Sac II
site. This resulted in a 1.7 kb fragment, YZ4, containing a
putative open reading frame. YZ4 was then subcloned
into the eukaryotic expression vector pcDNA3 (Invitro-
gen) and the resultant plasmid, pcDNA3/REP2, was trans-
fected into COS-1 using lipofectamine according to the
manufacturer's directions (Life Science Technologies)
with 12 µg plasmid DNA and 45 µL lipofectamine solu-
tion. Cells were cultured for 72 hours, and 5 mM sodium
butyrate was added to culture medium 16 hours before
lysis. Total cell membranes were prepared as described
previously [23].
Ligand binding analysis
Saturation isotherm ligand binding experiments were per-
formed using 15–20 µg of membrane protein incubated
with increasing concentrations of [3H] PGE2 at 30°C for 2
hours, in binding buffer (25 mM KPO4, pH6.2, 10 mM
MgCl2, and 1 mM EDTA). The reaction was stopped by
adding 1 ml of ice-cold binding buffer followed by rapid
filtration on Inotech IH-201-A21 glass fiber filters em-
ploying an Inotech 96 well filtration manifold (Inotech
Biosystems, Lansing, MI). Filters then were washed 3
times with binding buffer, dried briefly and counted in a
Beckman LS 6500 multi-purpose scintillation counter.
Nonspecific binding was defined as the radioactivity re-
maining bound to the filter in the presence of 50 µM un-
labelled PGE2. For competition binding assays, 20 µg of
membrane protein was incubated with 1 nM [3H]PGE2
and varying concentrations of unlabeled competitors. Re-
actions were carried out as above.
cAMP measurements
COS1 cells were transiently transfected with the EP2 recep-
tor expression plasmid were distributed onto 24-well
plates. The medium was replaced 24 hours later and incu-
bated one additional hour at 37°C in 450 µL DMEM plus
0.25 mM 3-isobutyl-1-methylxanthine (IBMX), and 40
mM indomethacin. Following this medium containing
varying amounts of butaprost free acid was added to each
well for 5 minutes. The reactions were stopped by addi-
tion of 500 µL of 10% trichloroacetic acid. cAMP measure-
ment of the cell lysates were performed by an EIA
according to manufacturer's instructions (Stratagene).
Isolation of renal microvessels and dissection of nephron 
segments
Renal preglomerular microvessels were isolated according
to a protocol from Chaudhari and Kirschenbaum [43].
Briefly, in anesthetized animals kidneys were exposed and
the renal artery cannulated. The kidneys were perfused
with 10 ml of ice cold normal saline, followed by 10 ml
of a 1% suspension of magnetized iron oxide (Fe3O4,
Aldrich) in normal saline. The cortex of the kidneys was
minced with a tissue press and homogenized using a Pol-
ytron homogenizer at moderate speed for 15 s × 2. Micro-
vessels were separated from nonvascular tissue in several
washing steps (in 1×  PBS) utilizing a strong magnet field.
Washing and separation were repeated after passing the
homogenate through 20-, 21- and 23-gauge needles, re-
spectively, until the suspension was mostly free of glomer-
uli and other nonvascular tissue. This technique provided
a large quantity of relatively pure preglomerular microves-
sels, with approximately 10–15 % of the suspension con-
sisting of attached glomeruli and early segments of
proximal tubules. Microdissection of nephron segments
was performed in the kidney of New Zealand White rabbit
as previously described [44]. The following segments were
dissected: glomeruli, proximal convoluted tubules (PCT),
proximal straight tubules (PST), thin limbs of Henle's
loop (tDL/tAL), thick ascending limb (TAL), distal convo-
luted tubules (DCT), cortical collecting ducts (CCD) and
medullary collecting duct (MCD) cells.
PCR ampification of Rabbit EP2 receptor Fragment
Total RNA was purified from dissected nephron segments
using Tri Reagent (Molecular Research Center) and re-
verse-transcribed to single-stranded cDNA using Moloney
murine leukemia virus reverse transcriptase and 2.5 µM of
random hexamers according to the manufacturer's proto-BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/14
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col (GeneAmp RNA PCR kit, Perkin Elmer Cetus, Nor-
walk, CT). The cDNAs were then amplified using EP2 and
GAPDH selective primers. Primers were selected from rab-
bit cDNA sequences. For rabbit EP2: 5'-TCC TCC CGA
AAA GAA AAG TGG-3' for sense and 5'-TGT TTA CCC
CGT TTT ATC AGG-3' for antisense; for rabbit GAPDH: 5'-
CGG AGC CAA AAG GGT CAT CAT-3' for sense and 5'-
TTT CTC CAG GCG GCA GGT CAG-3' for antisense. These
primers were used to amplify a 336 bp of EP2 cDNA frag-
ment and 411 bp of GAPDH cDNA fragment. PCR reac-
tions were carried out in 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 2.5 mM MgCl2, 0.2 mM dNTPs and 1 µM prim-
ers at 94°C for 0.5 min, 60°C for 0.5 min, and 72°C for 1.0
min for 35 cycles in a Perkin Elmer Cetus 9600 thermal cy-
cler. PCR products were separated by 1% agarose gel and
further confirmed by Southern hybridization and se-
quencing.
Culture of rabbit aortic smooth muscle cells (VSMCs), cor-
tical collecting duct cells (CCD), glomerular mesangial 
cells (MCs) and renal medullary interstitial cells (MICs)
The aorta was cut open in a longitudinal section and the
thin layer of endothelial cells was removed using a cotton-
tipped applicator. The aorta was cut into small pieces and
suspended in DMEM medium containing 20 % FCS and
grown in a culture dish in standard incubation at 37°C.
One week later, the VSMCs had outgrown from the tissue
suspension, and were transferred to a new flask. The me-
dium was changed every other day, the identity of the VS-
MCs was confirmed by α -actin fluorescence staining as
described [45]. Glomerular MCs, CCD cells and MICs
were cultured as we previously reported [22,44,46].
Solution hybridization/RNase protection assays
RNase protection assays were performed as described pre-
viously [22]. A Hind III fragment of the rabbit EP2 recep-
tor located in the the 3' untranslated region (3'UTR) was
subcloned into pBluescript SK(-) plasmid (Stratagene).
Plasmids containing rabbit EP1 (250 bp) [22] EP2 (322
bp), EP3 (466 bp) [24] and EP4 (328 bp) [23] were used
to synthesize cRNA probes for solution hybridization of
total RNA from various tissues. Briefly, the fragments of
EP1, EP2, EP3 and EP4 cDNA were subcloned in pBluscript
SK(-) vector, and the antisense orientation was deter-
mined by dideoxy-DNA sequencing. Radiolabeled ribo-
probes were synthesized from linearized plasmid DNA (1
µg) transcribed in vitro with 10 U of T3 RNA polymerase
by using MAXIscript™ kit (Ambion) for 1 hour at 37°C in
a total reaction volume of 20 µl. The reaction buffer con-
tained 10 mM dithiothreitol (DTT), 0.5 µM of ATP, CTP,
and GTP, 2.5 µM of UTP, and 5 µl of 800 Ci/mmol [α -32P]
UTP at 10 mCi/ml (Dupont NEN). Hybridization buffer
included 80% deionized formamide, 100 mM sodium ci-
trate, pH6.4, 300 mM sodium acetate, pH6.4 and 1 mM
EDTA (RPAII, Ambion). Twenty micrograms of total
RNAs from rabbit tissues, preglomerular vessels, cultured
cells were incubated at 45°C overnight in hybridization
buffer with 1 ×  105 cpm labeled riboprobe. After hybridi-
zation, ribonuclease digestion (20 mg/ml) was carried out
at 37°C for 30 minutes. Precipitated protected fragments
were separated on a 4% polyacrylamide gel at 200 V for
3.5 hours. End-labeled 100 bp DNA markers were used as
molecular weight standards (Promega). The gel was ex-
posed to Kodak XAR-5 film overnight at -80°C, with inten-
sifying screens.
In situ hybridization
In situ hybridization was performed as previously de-
scribed [22]. Rabbit uterus and kidney were fixed in 4%
paraformaldehyde, and embedded in paraffin. Seven µm
sections were cut and hybridized with [35S]-labeled ribo-
probe used in the RNase protection assays at 55°C for 18
hours. Following hybridization, sections were washed at
50°C in 50% formamide, 2X SSC, and 100 mM β -mercap-
toethanol for 60 minutes. Sections were treated with
RNase A (10 µg/ml) at 37°C for 30 minutes, followed by
washes in 10 mM Tris, 5 mM EDTA, 500 mM NaCl at
37°C; 2X SSC at 50°C; and 0.1X SSC at 50°C. Slides were
dehydrated with ethanol containing 300 mM ammonium
acetate. Photomicrographs were taken from slides dipped
in emulsion (Ilford K5, Knutsford, Cheshire, England) di-
luted 1:1 with 2% glycerol and exposed for 7 days at 4°C.
After developing in Kodak D-19, slides were counter-
stained with hematoxylin and eosin. Photomicrographs
were taken by a Zeiss Axioskop microscope using dark-
field optics.
Data analysis
All binding assays and cAMP measurements were plotted
using PRISM (GraphPad, San Diego, CA).
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